

Preliminary program

2nd Frontiers in Antibiotic Drug Discovery FiADD

June 17

12:00 Registration & light lunch

Chair: Anders Karlén, Uppsala University, Sweden

13:00 Accessing the Untapped Chemical Space Favored by Evolution for Antibacterial Discovery

David Pompliano, Sanderling Consulting LLC, USA

13:45 Ultrashort and stable antimicrobial peptides, design principles and applications

Johan Svenson, RISE, Gothenburg, Sweden

14:15 Coffee

Chair: Katarina Färnegårdh, SciLifeLab, Sweden

14:45 Targeting bacterial virulence as a strategy to combat pathogenic bacteria

Fredrik Almqvist, Umeå University, Sweden

15:15 Antisense and peptide antibacterials

Fredrik Björkling, University of Copenhagen, Denmark

15:45 Break

16:00 Structure-based design of next-generation aminoglycoside antibiotics

Sven N. Hobbie, Principal Investigator, University of Zurich, Switzerland

16:30-17:30 Poster session

18:00 Dinner

June 18

Chair: Eva Garmendia, Uppsala University, Sweden

09:00 Evaluating resistance problems in antibiotic development, and an overview of the current clinical pipeline

Diarmaid Hughes, Uppsala university, Sweden

09:45 Restoring the failing ecosystem of antibiotic R&D - where are we today?

Anna Zorzet, Uppsala Antibiotic Center, ReAct Europe, Uppsala, Sweden

10:15 Coffee

Chair: Diarmaid Hughes, Uppsala University, Sweden

10:45 Structure-based design of carbapenemase inhibitors

Annette Bayer, The Arctic University of Norway, Norway

Preliminary program

2nd Frontiers in Antibiotic Drug Discovery FiADD

- 11:15 Ultrafast antibiotic susceptibility testing
Johan Elf, Uppsala University, Sweden
- 11:45 Break
- 12:00 Bench to bedside: specific challenges and opportunities for antibacterial startups
Sven N. Hobbie, Co-founder and CEO, Juvabis AG, Switzerland
- 12:30 Panel discussion on Key issues for the next decade in the antibacterial area
Moderator: Eva Garmendia, Uppsala University, Sweden
- 13:00 End